Analysis of dermatologic events in vemurafenib-treated patients with melanoma

Oncologist

Volumn 18, Issue 3, 2013, Pages 314-322

  Lacouture, Mario E ^a   Duvic, Madeleine ^b   Hauschild, Axel ^c   Prieto, Victor G ^d   Robert, Caroline ^e   Schadendorf, Dirk ^f   Kim, Caroline C ^g   McCormack, Christopher J ^h   Myskowski, Patricia L ^a   Spleiss, Olivia ⁱ   Trunzer, Kerstin ⁱ   Su, Fei ^j   Nelson, Betty ^k   Nolop, Keith B ^l   Grippo, Joseph F ^j   Lee, Richard J ^j   Klimek, Matthew J ^j   Troy, James L ^m   Joe, Andrew K ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b University of Texas Health Science Center   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g HARVARD MEDICAL SCHOOL   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j HOFFMANN LA ROCHE INC   (United States)

^k GENENTECH INC   (United States)

^l PLEXXIKON INC   (United States)

^m MEDICAL COLLEGE OF WISCONSIN   (United States)

more..

Author keywords

Cuscc; Dermatologic; Keratoacanthoma; Vemurafenib

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIHISTAMINIC AGENT; B RAF KINASE; DACARBAZINE; KERATOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PREDNISOLONE; RAF PROTEIN; STEROID; VEMURAFENIB;

ARTICLE; DARIER DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; FOLLICULITIS; GENETIC ANALYSIS; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MELANOMA; MUTATION; MUTATIONAL ANALYSIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEQUENCE ANALYSIS; SKIN ABRASION; SKIN CARCINOMA; SUNBURN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875453915     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0333     Document Type: Article

References (35)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
2. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
3. Yazdi AS, Palmedo G, Flaig MJ et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-1162.
4. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8:426-433.
5. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
6. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
7. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
8. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
9. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-5467.
10. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6: 803-812.
11. Hwang S, Schwartz RA. Keratosis pilaris: A follicular hyperkeratosis. Cutis 2008;82: 177-180.
12. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366:480-481.
13. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365:1448-1449.
14. Zimmer L, Livingstone E, Hillen U et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012;148:357-361.
15. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012;30: 2375-2383.
16. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994;30:1-19.
17. Kossard S, Tan KB, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008;30:127-134.
18. Ko CJ. Keratoacanthoma: Facts and controversies. Clin Dermatol 2010;28:254-261.
19. Kong HH, Cowen EW, Azad NS et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-172.
20. Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27: e59-e61.
21. Dubauskas Z, Kunishige J, Prieto VG et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-23.
22. Arnault JP, Mateus C, Escudier B et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18: 263-272.
23. Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(suppl 15):8503.
24. Trefzer U. BREAK-2: A phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF (V600E/K) positive metastatic melanoma. Abstract presented at: 8th International Melanoma Congress of the Society for Melanoma Research; November 9-13, 2011; Tampa, FL.
25. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
26. Lacouture ME, McArthur GA, Chapman PB et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28(suppl 15):8592.
27. Corominas M, Kamino H, Leon J et al. Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A 1989;86:6372-6376.
28. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-321.
29. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215.
30. Poulikakos PI, Zhang C, Bollag G et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-430.
31. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: A review. Am J Dermatopathol 2009;31:561-573.
32. Anforth RM, Blumetti TC, Kefford RF et al. Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167: 1153-1160.
33. Alloo A, Garibyan L, LeBoeuf N et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012;148: 363-366.
34. Anforth R, Bluemetti TC, Mohd Affandi A et al. Systemic retanoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012;30: e165-e167.
35. Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025-1039.